Abstract
Four cases with classic skin manifestations and histologic evidence of dermatomyositis are presented. No occult malignancies were found. After conventional therapy with corticosteroids, hydroxychloroquine and/or methotrexate proved to be limited by side effects or an inadequate clinical response, a therapeutic trial of mycophenolate mofetil was instituted. This relatively new drug, which inhibits lymphocyte proliferation, was effective [with a mean duration of treatment of 13 months (range 6-20)] at controlling cutaneous disease activity, resulting in a decrease of the steroid dose.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1542-1545 |
| Number of pages | 4 |
| Journal | Journal of Rheumatology |
| Volume | 27 |
| Issue number | 6 |
| State | Published - Jun 26 2000 |
Keywords
- Dermatomyositis
- Mycophenolate mofetil
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
Fingerprint Dive into the research topics of 'Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases'. Together they form a unique fingerprint.
Cite this
Gelber, A. C., Nousari, H. C., & Wigley, F. M. (2000). Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases. Journal of Rheumatology, 27(6), 1542-1545.